

IN THE CLAIMS

1. (Currently Amended) A method for treating graft-versus-host ~~an autoimmune~~ disease of the mouth, comprising: ~~topically contacting swishing for at least one minute in~~ the mouth of a patient in need of such treatment an effective amount of ~~with~~ a liquid formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide, and optionally a non-steroidal anti-inflammatory agent.
2. (Original) The method of Claim 1, wherein said purine analog is a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.
3. (Previously Amended) The method of Claim 1, wherein said formulation includes azathioprine or a pharmaceutically acceptable salt thereof.
4. (Canceled)
5. (Previously Amended) The method of Claim 3, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.
6. (Previously Amended) The method of Claim 3, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.
7. (Canceled)
8. (Canceled)
9. (Currently Amended) The method of claim 1, wherein said swishing step of topically contacting includes rinsing the mouth of said patient with said formulation for at least one minute; and swallowing said formulation after said step of rinsing.
10. (Currently Amended) The method of claim 3, wherein said swishing step of topically contacting includes rinsing said the mouth with said formulation for at least one minute, and thereafter expectorating said formulation without swallowing.
11. (Original) The method of Claim 1, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroid anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.
12. (Canceled)
13. (Canceled)
14. (Cancelled)
15. (Canceled)

16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Currently Amended) A method for preventing graft-versus-host -an autoimmune disease of the mouth, comprising topically contacting: swishing for at least one minute in the mouth of a patient in need of such treatment an effective amount of with a liquid formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide, and optionally a non-steroidal anti-inflammatory agent.
20. (Original) The method of Claim 19, wherein said purine analog is a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.
21. (Previously Amended) The method of claim 19, wherein said formulation includes azathioprine or a pharmaceutically acceptable salt thereof.
22. (Canceled)
23. (Previously Amended) The method of claim 21, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.
24. (Previously Amended) The method of claim 21, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.
25. (Canceled)
26. (Canceled)
27. (Currently Amended) The method of claim 19, wherein said swishing step of topically contacting includes rinsing the mouth of said patient with the formulation for a least one minute; and swallowing said formulation after said step of rinsing.
28. (Currently Amended) The method of claim 21, wherein said swishing step of topically contacting includes rinsing said the mouth with said formulation for at least one minute, and thereafter expectorating said formulation without swallowing.
29. (Original) The method of Claim 19, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroid anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.

- 30. (Canceled)
- 31. (Canceled)
- 32. (Canceled)
- 33. (Canceled)
- 34. (Canceled)
- 35. (Canceled)
- 36. (Canceled)
- 37. (Canceled)
- 38. (Canceled)
- 39. (Previously Added) The method of claim 1, wherein said non-steroidal anti-inflammatory agent is a member selected from the group consisting of indomethacin, sulindac, ibuprofen, aspirin, naproxen and tolmetin.